Thompson M, Akyol M S
J Int Med Res. 1977;5 Suppl 2:96-9.
A double-blind crossover trial of fenclofenac was untertaken to compare the short-term effects of phenylbutazone (Butacote) therapy with fenclofenac therapy (1200 mg daily) in 23 patients suffering from ankylosing spondylitis. The patients were randomly allocated to each of the test drugs for a period of two weeks, following wash-out periods of paracetamol for four days. The results favoured Butacote therapy in a dosage of 300 mg daily in the expressed preferences of both the patients and the physicians conducting the trial. Butacote was also better tolerated, as no severe side-effects occurred during treatment, whereas five patients developed a widespread rash during the period of fenclofenac therapy. No significant differences were seen between the two drugs in terms of clinical measurements of pain, morning stiffness, spinal movements, chest expansion, and abduction of the hips. Butacote was shown to cause some significant depletion of haemoglobin level, probably due to water retention, and Butacote also reduced the serum urate level to a significant degree.
对23例强直性脊柱炎患者进行了双氯芬酸的双盲交叉试验，以比较保泰松（Butacote）疗法与双氯芬酸疗法（每日1200毫克）的短期效果。在停用对乙酰氨基酚4天后，患者被随机分配接受每种试验药物治疗两周。在患者和进行试验的医生明确表示的偏好中，结果显示每日剂量为300毫克的保泰松疗法更优。保泰松的耐受性也更好，因为治疗期间未出现严重副作用，而在双氯芬酸治疗期间有5名患者出现了广泛皮疹。在疼痛、晨僵、脊柱活动、胸廓扩张和髋关节外展的临床测量方面，两种药物之间未观察到显著差异。保泰松显示会导致血红蛋白水平显著降低，可能是由于水潴留，并且保泰松还能显著降低血清尿酸水平。
